Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged ≥18 Years — Long Beach, California, April 1–December 10, 2020

Yomogida, Kyle; Zhu, Sophie; Rubino, Francesca; Figueroa, Wilma; Balanji, Nora; Holman, Emily J.

doi:10.15585/mmwr.mm7037a2

Cited by 79 publications

(68 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Post-acute sequelae of COVID-19 (PASC), also colloquially termed “Long COVID” or “long-haul COVID-19” is a clinical entity that has gained recognition as the pandemic continued into its second year in 2021. While there is no consensus for a single definition, in general, PASC refers to the persistence of symptoms for more than three months after the onset of symptoms 85 . The most common reported symptoms are shortness of breath and fatigue, however an extensive list of symptoms involving multiple systems has been described.…”

Section: Extrapulmonary Manifestations Of Covid-19mentioning

confidence: 99%

COVID-19 Pathogenesis and Clinical Manifestations

Acosta¹,

Garrigos²,

Marcelin³

et al. 2022

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

show abstract

Section: Extrapulmonary Manifestations Of Covid-19mentioning

confidence: 99%

COVID-19 Pathogenesis and Clinical Manifestations

Acosta¹,

Garrigos²,

Marcelin³

et al. 2022

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

show abstract

“…We assumed that individuals with asymptomatic infection did not die or require any inpatient or outpatient treatment, but could experience PASC complications. The term PASC, also known as 'long COVID', is used to describe the post-acute sequelae and long-term symptoms that can be experienced from weeks to months by persons recovering from COVID-19 [40]. Symptomatic cases were moved further into the decision tree according to outcome probabilities informed by the individual's health state specific efficacy against symptomatic disease and against hospitalization.…”

Section: Modelmentioning

confidence: 99%

Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Fusco

Marczell²,

Deger

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: As the body of evidence on COVID-19 and post-vaccination outcomes continues to expand, this analysis sought to evaluate the public health impact of the Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, during the first year of its rollout in the US. Methods: A combined Markov decision tree model compared clinical and economic outcomes of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) versus no vaccination in individuals aged ≥12 years. Age-stratified epidemiological, clinical, economic, and humanistic parameters were derived from existing data and published literature. Scenario analysis explored the impact of using lower and upper bounds of parameters on the results. The health benefits were estimated as the number of COVID-19 symptomatic cases, hospitalizations and deaths averted, and Quality Adjusted Life Years (QALYs) saved. The economic benefits were estimated as the amount of healthcare and societal cost savings associated with the vaccine-preventable health outcomes. Results: It was estimated that, in 2021, the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) contributed to averting almost 9 million symptomatic cases, close to 700,000 hospitalizations, and over 110,000 deaths, resulting in an estimated $30.4 billion direct healthcare cost savings, $43.7 billion indirect cost savings related to productivity loss, as well as discounted gains of 1.1 million QALYs. Scenario analyses showed that these results were robust; the use of alternative plausible ranges of parameters did not change the interpretation of the findings. Conclusions: The Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) contributed to generate substantial public health impact and vaccine-preventable cost savings in the first year of its rollout in the US. The vaccine was estimated to prevent millions of COVID-19 symptomatic cases and thousands of hospitalizations and deaths, and these averted outcomes translated into cost-savings in the billions of US dollars and thousands of QALYs saved. As only direct impacts of vaccination were considered, these estimates may be conservative.

show abstract

“…При эндемичных коронавирусных инфекциях боль в суставах и мышцах встречается менее чем в 10 % случаев, однако уже в первых публикациях, касающихся скелетно-мышечных проявлений COVID-19, была отмечена большая частота артралгий (15 % пациентов) и миалгий (44 % случаев) [1,5]. В исследованиях, посвященных клиническим проявлениям COVID-19, частота различных скелетно-мышечных симптомов отличается, однако в большинстве из них частота артралгий / миалгий в остром периоде превышает 50 % [11,12]. По данным Z.…”

Section: частота артралгии и миалгии в остром периоде Covid-19 и при ...unclassified

“…В работе K. Yomogida и соавт., включавшей 791 больного, опрошенного через 2 мес после получения положительного результата теста ПЦР на SARS-CoV-2 (медиана -202 дня; диапазон -78-368 дней), о наличии артралгии / миалгии после перенесенной инфекции сообщали уже 10,9 % больных [11].…”

Section: частота артралгии и миалгии в остром периоде Covid-19 и при ...unclassified

“…Drugs used in COVID19 with potential effects on musculoskeletal system (adapted from [38]) О б з о р пребывания в больнице [10]. Однако в другом исследовании постковидные проявления наблюдали чаще у женщин старше 40 лет [11]. С более высокой вероятностью сохранения усталости (отношение шансов (ОШ) с 95 % доверительным интервалом (ДИ) -1,08, p = 0,003), артралгии (ОШ -1,07, p = 0,012) и миалгии (ОШ -1,08, p = 0,015) было связано увеличение индекса массы [10].…”

Section: клиническая характеристика артралгии и миалгии в остром пери...unclassified

See 1 more Smart Citation

Musculoskeletal manifectations of the new coronavirus infection: focus on arthralgia and myalgia

Клименко

Демидова

et al. 2022

Klinicist

View full text Add to dashboard Cite

The new coronavirus infection (COVID-19) is associated with a wide spectrum of various clinical manifestations including involvement of the musculoskeletal system which can persist for a long time after the infection. Supposedly, pathogenesis of musculoskeletal manifestations of COVID-19 is primarily caused by systemic inflammation accompanied by cytokine hyperexpression (interferon γ, interleukins 1β, 6, 8, 17, tumor necrosis factor α), as well as hypoxia leading to overproduction of inflammatory cytokines, activation of bone reabsorption by osteoclasts and subsequent decrease of mineral bone density and osteonecrosis in some cases. Additionally, some drugs prescribed to patients with COVID-19 (some antiviral drugs and glucocorticoids) should also be taken into account as they can lead to development of musculoskeletal pathology. In the acute period of COVID-19, myalgias are common, but in rare cases myositis with proximal muscular weakness and increased levels of creatine phosphokinase, lactate dehydrogenase can occur. Arthralgias in the acute period of COVID-19 are rarer than myalgias. In the studies of clinical manifestation of COVID-19, frequency of arthralgias and myalgias in the acute period is between 15.5 and 50 %. After COVID-19, frequency of arthralgias and myalgias gradually decreases, however there are cases of long-term joint and muscle pains, as well as post-viral arthritis, development of arthritis in the context of various autoimmune disorders. Myalgias and arthralgias during COVID-19 usually regress spontaneously and in most patients do not require prescription of antipain medications, but in some cases pain management is necessary. Use of non-steroid anti-inflammatory drugs and vitamin D during COVID-19 is a safe and effective method of pain management, including myalgia and arthralgia. Rehabilitation programs play an important role in improvement of functional state and patient recovery after moderate and severe COVID-19.

show abstract

Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged ≥18 Years — Long Beach, California, April 1–December 10, 2020

Cited by 79 publications

References 9 publications

COVID-19 Pathogenesis and Clinical Manifestations

COVID-19 Pathogenesis and Clinical Manifestations

Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Musculoskeletal manifectations of the new coronavirus infection: focus on arthralgia and myalgia

Contact Info

Product

Resources

About